Cox Troy 4

What Happened Troy Cox, a director of MapLight Therapeutics, received two awards on June 23, 2026: 7,864 restricted stock units (RSUs) and a derivative award covering 29,804 shares (a stock option). Both items are reported with an acquisition price of $0.00 (they are grants); the Form 4 shows $0 cash paid. These awards were granted under MapLight’s 2025 Equity Incentive Plan as part of the company’s non‑employee director compensation policy.

Key Details

• Transaction date: June 23, 2026; Form 4 filed June 25, 2026 (timely).
• Reported acquisition price: $0.00 for both the 7,864 RSUs and the 29,804‑share option grant.
• Vesting: Both the RSUs and the option shares vest in three equal annual installments beginning June 23, 2027, subject to the reporting person’s continued service.
• RSU conversion: Each RSU represents a contingent right to one share of common stock.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Footnotes: Grants made under the 2025 Equity Incentive Plan and per the issuer’s non‑employee director compensation policy (see F1–F3).

Context RSUs are rights to receive shares in the future (one RSU = one share on vesting); the 29,804‑share entry is a stock option grant (a derivative) that vests over time — neither was exercised or sold. Director grants like these are routine compensation and do not by themselves indicate buying or selling sentiment. The filing appears timely (filed two days after the grant date).